Robert Carroll

Partner, Head of Investor Relations and Responsible Investment Strategy


Rob joined Sofinnova Partners in January 2020 from PwC’s Global Fundraising Advisory Platform,  which he helped establish and co-led. Rob has over a decade of experience working with institutional investors and raising capital for alternative assets. Prior to PwC, he was at Mercury Capital Advisors, a global private fund raising and investment advisory firm, that has its origins in Merrill Lynch. Here, he also supported the needs of institutional investors and successfully raised capital across the alternative assets spectrum.

Prior to his career in private placement, Rob worked as a Principal Scientist and project lead at Pfizer, directing his efforts to the development of assets from discovery through pre-clinical and into clinical development. He has also worked at GSK and Eli Lilly.

Rob holds a Ph.D. in Chemistry (Prof. Willie Motherwell, University College London) and completed postdoctoral research at Brock University, Canada in the labs of Prof. Tomáš Hudlický, with a focus on the semi-synthesis of morphine and its analogues. This work was carried out in collaboration with Noramco (then a part of Johnson and Johnson) and is the subject of a number of patents.